Preliminary data from the Beamion LUNG-1 trial (NCT04886804) revealed a 50% response rate in HER2-mutant solid tumors, with updated findings in NSCLC patients reporting an ORR of 72% and a DCR of 95.5%, along with a favorable safety profile marked by low incidences of serious gastrointestinal and hepatic toxicities [189]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.